FINWIRES · TerminalLIVE
FINWIRES

UISEE Technologies Launches Up to HK$872 Million Hong Kong IPO

By

UISEE Technologies (HKG:1511) launched its Hong Kong initial public offering on Tuesday, seeking to raise about HK$872 million from the deal.

The China-based autonomous driving company is offering 14.5 million shares at HK$60.30 each, according to a Hong Kong bourse filing.

The offering comprises 723,100 shares for Hong Kong investors and 13.7 million shares for international investors, subject to reallocation and the offer size adjustment option.

Allocation results are due by May 19, ahead of the company's planned trading debut on May 20.

Net proceeds will be used mainly to enhance research and development capabilities and strengthen solution offerings.

The funds will also be used for domestic and overseas business expansion, commercialization efforts, strategic investments, and working capital and general corporate purposes.

CITIC Securities (Hong Kong) is acting as the sole sponsor, while CLSA is serving as sponsor-overall coordinator.

CLSA, BOCOM International Securities, DBS Asia Capital, and China Galaxy International Securities (Hong Kong) are acting as overall coordinators, joint global coordinators, joint bookrunners, and joint lead managers, alongside Hong Tai Securities.

Futu Securities International (Hong Kong), CEB International Capital, uSmart Securities, CNCB (Hong Kong) Capital, Quam Securities, Lego Securities, Patrons Securities, and SBI China Capital Financial Services are acting as joint bookrunners and joint lead managers.

Related Articles

Asia

Shenzhen LDROBOT Soars 103% in Hong Kong Trading Debut

Shenzhen LDROBOT's (HKG:1236) shares opened 102.9% above their initial public offering price in a stellar Hong Kong debut on Monday morning.The Chinese robotics company opened at HK$53.50 per share, well above the offer price of HK$26.36.

HKG:1236
Asia

Concord Healthcare to Issue HK$68 Million Convertible Bonds to CSPC Pharma Unit

Concord Healthcare (HKG:2453) agreed to issue HK$68 million of convertible bonds to a unit of CSPC Pharmaceutical (HKG:1093), according to a Monday Hong Kong bourse filing.The oncology healthcare service provider said Dragon Merit will subscribe to the 2% convertible bonds due in April 2027.The bonds are convertible into as many as 40 million Hong Kong-listed shares at an initial conversion price of HK$1.70 per share, representing a premium of about 14.1% to the stock's last closing price.Net proceeds of about HK$63.1 million will mainly be used to repay loans and supplement working capital.Concord Healthcare said the investment is expected to deepen cooperation with CSPC Pharmaceutical in the oncology healthcare sector.

HKG:1093HKG:2453
Asia

Alterity Therapeutics Says Peer-Reviewed Study Validates its Approach to Multiple System Atrophy; Shares Fall 9%

Alterity Therapeutics (ASX:ATH) said findings of a study published in the NeuroImage journal support quantitative susceptibility mapping as an objective imaging biomarker to facilitate the earlier diagnosis of multiple system atrophy (MSA), according to a Monday filing with the Australian bourse.Alterity is advancing its ATH434 lead candidate into a phase three program for multiple system atrophy, a neurodegenerative disease that leads to the failure of the autonomic nervous system and impaired movement.The company said it used quantitative susceptibility mapping in a phase two trial in which ATH434 helped improve diagnostic accuracy and provided "objective evidence of target engagement."The peer-reviewed publication validates the company's approach and "reinforces the role of [quantitative susceptibility mapping] as a biomarker for iron-modulating therapies in MSA," Alterity CEO David Stamler said.The company's shares fell 9% in recent Monday trade.

ASX:ATH